Mahon Paul A's Form 4/A amendment
AmendedUnited Therapeutics Corp (UTHR) · filed Mar 16, 2023
- Accession no.
- 0001415889-23-005016
- Filed
- Mar 16, 2023
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Apr 22, 2022
This filing lists no transactions. It carries over 5 transactions from the original filing that it did not restate. Open-market sales total $1.14M.
This amendment restates part of 0001415889-22-004230 (filed Apr 22, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mahon Paul ACIK 0001231589 | Officer (EVP & GENERAL COUNSEL) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001415889-22-004230 (filed Apr 22, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | MOption exerciseAcquired | +6,000 | $111.00 | +$666,000 | 42,487 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −600 | $187.20F2 | −$112,320 | 41,887 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −1,599 | $188.77F3 | −$301,843.23 | 40,288 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −3,801 | $189.66F4 | −$720,897.66 | 36,397 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | MOption exerciseDisposed | −6,000 | $0.00 | $0 | 40,552 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
This transaction was executed in multiple trades at prices ranging from $186.855 to $187.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $188.24 to $189.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $189.25 to $190.125. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects the correction of a clerical error in the reporting person's Form 4 filed on April 22, 2022, which error caused the reporting person's common stock holdings to be overreported by 90 shares in such Form 4 and in the reporting person's subsequently filed Forms 4.